Anjaniputra Hospitals
Anjaniputra
Hospitals · Est. care
Book consultation
Near-home oncology · Multi-speciality care

Cancer care that comes closer to home.

Anjaniputra Hospitals is building India's first true near-home cancer-care chain — an 8-km grid of uniform 40-bed units anchored to a comprehensive hub, surrounded by full multi-speciality medicine for kidney, liver, HIV/AIDS, cardiac and critical care.

Book a consultation →Explore oncology care
NABH-alignedJCI-aligned protocolsAERB Radiation SafetyISO 9001
Anjaniputra Hospitals reception lobby
26+
Specialist physicians on panel
8 km
Target distance to every patient
720
Operational beds by FY36 (plan)
18
Cancer-care units (FY36 target)
From the Chairman

"We treat the patient first — the disease comes second."

When we set out to build Anjaniputra Hospitals, the question we kept returning to was a simple one — would I send my own mother here? Every protocol, every consultant we hire, every piece of equipment we install is judged against that single test.

India's most punishing illnesses — advanced cancers, end-stage renal disease, decompensated liver failure, complex cardiac events — do not wait for a patient to travel three cities for a second opinion. Our model brings the second opinion to the patient's neighbourhood, backed by a tumour-board, a closed ICU and JCI-aligned protocols that don't waver because someone is short of time, money, or both.

We are a debt-free, physician-led platform. We will scale only as fast as our standards allow. That is a promise.

Ravi Tej
Chairman · Anjaniputra Hospitals
Why Anjaniputra for critical illness

When the diagnosis is serious, the system around it has to be flawless.

Critical ailments — late-stage cancers, multi-organ failure, complex cardiac events, post-transplant care — punish hesitation and reward systems. This is where we have built our deepest moats.

A tumour board on day one

Every confirmed cancer is reviewed by medical, surgical and radiation oncologists together — not handed from desk to desk.

Closed ICU, intensivist-led

24×7 critical-care physicians own ventilation, sepsis bundles and escalation — not a rotating roster of consultants.

Single accountable physician

One named clinician owns your treatment plan end-to-end, supported by a care manager who returns your calls.

International protocols, audited

NCCN, ESMO and JCI-aligned pathways with mortality, morbidity and near-miss review at chain level.

Cardio-oncology integration

Cancer survivors gain a cardiology programme built around chemotherapy cardiotoxicity — a gap most hospitals miss.

Transparent estimates, written

Every critical-care estimate is shared in writing — including the worst case — before admission.

Speed of care

Treatment turnaround time — measured, monitored, improved.

In critical illness, every hour matters. We publish our turnaround targets because accountability is the first step to improvement. These are our baseline commitments across outpatient, diagnostic and treatment pathways.

Why turnaround time defines outcomes

  • Earlier cancer staging means earlier, more curative treatment.
  • Faster blood-culture results cut sepsis mortality by hours.
  • Shorter door-to-balloon times protect heart muscle in heart attacks.
  • Repeated delays in chemotherapy erode survival and trust; we track both.
01Outpatient appointment

Booked online or walk-in; specialist availability within 24 hours for urgent cases.

Same day
02Imaging report (CT / MRI / X-ray)

Routine scans reported within one business day; emergency reads within the hour.

≤ 4 hours
03Laboratory results

Routine biochemistry, haematology and microbiology; critical values called immediately.

≤ 6 hours
04Biopsy & histopathology

Standard H&E with provisional report; IHC and special stains within 5–7 days.

≤ 48 hours
05Cancer staging workup

Complete CT/PET-CT, labs, tumour markers and multidisciplinary review.

≤ 72 hours
06First chemotherapy cycle

From confirmed diagnosis to first infusion, assuming workup is complete.

≤ 7 days
07Emergency intervention

Door-to-needle and door-to-balloon times monitored against international benchmarks.

≤ 30 min
08Second opinion

Remote case review by the relevant tumour-board or specialist panel.

≤ 48 hours

Turnaround times are targets for standard operating conditions and may vary by acuity, equipment availability, third-party reference-lab dependency and statutory holidays. Urgent and emergency cases are always prioritised.

Compassionate care at Anjaniputra Hospitals
About Anjaniputra

A debt-free, physician-led oncology platform — engineered to scale with discipline.

We operate a 40-bed, asset-light specialty hospital with validated unit economics. The plan: replicate this proven cell across an 8-km metropolitan grid, then into Tier-2 and Tier-3 cities — because cancer care is visit-intensive and proximity is the single biggest determinant of access, adherence and outcomes.

Surrounding the cancer core is full multi-speciality medicine — nephrology, hepatology, HIV/AIDS care, interventional cardiology, critical care, and surgery — delivered with international protocols and Indian warmth.

Patient-first protocols
Daily tumour-board review
Cashless insurance desk
Concierge medical travel
Centres of excellence

Twelve specialities. One unified standard of care.

Every speciality is led by fellowship-trained consultants and powered by latest-generation equipment under JCI-aligned protocols.

⚕

Comprehensive Oncology

Medical, surgical & radiation oncology with daily tumour board review.

◉

Radiation Oncology (LINAC)

Image-guided IMRT & SBRT with AERB-compliant bunkers.

◈

Nephrology & Kidney Care

CKD, dialysis, transplant work-up and Nephrospec™ non-invasive renal care.

◆

Hepatology & Liver Care

Cirrhosis, hepatitis B/C, fatty liver, HCC screening and transplant referral.

✦

HIV / AIDS Medicine

Confidential ART initiation, adherence, opportunistic-infection care and counselling.

♥

Interventional Cardiology

Primary PCI, structural heart and 24×7 cath-lab readiness.

▣

Critical Care Medicine

Intensivist-led ICU with closed-loop sepsis & ventilation protocols.

◐

Gastro-Intestinal Surgery

Minimally invasive GI oncology and bariatric procedures.

❋

Bio-Regenerative Medicine

Swiss-rooted cellular protocols, integrated with conventional oncology care.

◎

Diagnostics & Molecular Pathology

High-field MRI, 128-slice CT, NGS and IHC for precision therapy.

◔

Pulmonology & Sleep

Bronchoscopy, asthma, sleep-disordered breathing, lung-cancer screening.

◇

Vascular & Endovascular

Limb salvage, AV-fistula, aortic and venous interventions.

Regenerative & cellular medicine

Where the body's own biology becomes the medicine.

Anjaniputra's regenerative-medicine programme is built on the European cellular-medicine lineage — Paul Niehans, Mikhail Voronoff and the modern bio-peptide schools — and delivered with Indian rigour. We use regenerative therapy to complement conventional medicine: to help tissues recover after surgery, to soften the burden of chemotherapy, and to support patients living with chronic disease.

Every regenerative protocol is governed by a written clinical pathway, an informed-consent process, and ethics-committee review. We will never offer a regenerative therapy as a "miracle alternative" to evidence-based care.

❋
Peptide & organ-specific therapy

Targeted bio-peptides developed from the European cellular-medicine tradition, used adjunctively to support tissue recovery.

❋
Autologous cell preparations

Patient-derived cellular products prepared in cleanroom conditions, with rigorous donor-screening and traceability.

❋
PRP & growth-factor therapy

Platelet-rich plasma protocols for orthopaedic, dermatologic and post-surgical recovery, image-guided where indicated.

❋
Exosome-based protocols

Carefully selected exosome preparations used under research-grade protocols, with informed consent and IRB review.

❋
Integrative oncology adjuncts

Regenerative protocols offered only alongside standard oncology care — never as a replacement for surgery, chemotherapy or radiation.

❋
Recovery & longevity programmes

Structured 6, 12 and 24-week recovery pathways combining cellular therapy, nutrition, physiotherapy and sleep medicine.

Regenerative-medicine outcomes vary by individual, indication and stage of disease. Our consultants will tell you honestly whether a programme is appropriate for you — and when it is not.

Cutting-edge technology · Personalised care

Decisions made on your biology — not on the average patient's.

Precision medicine is only as good as the data it stands on. We invest in the diagnostics that change the treatment plan — comprehensive DNA analysis, liquid biopsy, advanced blood culture and AI-assisted imaging — so that your therapy is calibrated to your genome, your tumour and your immune system.

Comprehensive DNA analysis

Germline and somatic next-generation sequencing (NGS) panels covering 500+ cancer-relevant genes, plus whole-exome where indicated, with pharmacogenomic reporting to guide drug selection and dosing.

Liquid biopsy & ctDNA

Circulating-tumour-DNA testing for treatment monitoring and early relapse detection, sampled from a routine blood draw.

Blood culture & molecular microbiology

Automated continuous-monitoring blood-culture systems with MALDI-TOF identification and PCR-based pathogen panels — actionable results in hours, not days.

Precision imaging

3T MRI, 128-slice CT with low-dose protocols, digital mammography with tomosynthesis, PET-CT referral network.

AI-assisted diagnostics

Radiology and pathology workflows augmented with FDA-cleared AI assist tools — always with a senior consultant signing every report.

Personalised treatment dashboards

Each patient receives a secure portal with their genomic report, treatment plan, vitals and a single point of clinical contact.

Privacy · HIPAA-aligned

Your health data is held to international standards.

  • • HIPAA-aligned data-handling for all health records, genomic data and imaging — equivalent to United States hospital standards.
  • • ISO 27001-aligned information-security controls; data encrypted at rest (AES-256) and in transit (TLS 1.3).
  • • Role-based access; every record access is logged and auditable.
  • • Genomic data stored separately from identifiers; re-identification requires multi-party authorisation.
  • • Patient consent is granular — you choose what is shared, with whom, and for how long.
  • • Independent annual security audit; breach-notification protocol within 72 hours, regardless of jurisdictional minimum.
Comprehensive treatment programmes

Medicine that reaches every organ system — with depth where it matters most.

Oncology is our anchor speciality, but our patients live in whole bodies. We deliver evidence-led programmes for cancer, kidney, liver, HIV/AIDS and cardiac disease — coordinated by a single care manager.

Image-guided linear accelerator
Cancer (Oncology)

Breast, lung, GI, head & neck, gynae-onc, haemato-onc — surgical, medical, radiation, palliative. NGS-guided targeted therapy and immunotherapy where indicated.

Kidney (Nephrology)

CKD staging, hypertension control, hemodialysis, peritoneal dialysis, transplant work-up and Nephrospec™ non-invasive renal-function support.

Liver (Hepatology)

Hepatitis B & C cure pathways, NAFLD/NASH, alcoholic liver disease, cirrhosis care, HCC surveillance, transplant referral.

HIV / AIDS

Confidential ART initiation per NACO guidelines, viral-load monitoring, opportunistic-infection prophylaxis, mental-health and adherence counselling.

Cardiology

Primary angioplasty, structural-heart interventions, heart-failure clinic, preventive cardiology — integrated with cancer survivorship (cardio-onc).

Critical Care

Closed ICU with intensivist coverage, sepsis bundles, ventilation protocols, ECMO referral pathway.

Strategic blueprint · FY27 → FY36

From one 40-bed unit to an 18-unit, 720-bed near-home network.

Network revenue is projected to scale from ≈ ₹58 Cr (FY27) to ≈ ₹661 Cr (FY36) at a blended ~26% EBITDA margin, with cumulative deployment of ≈ ₹625 Cr — staged, de-risked and physician-led. (Source: Anjaniputra Hospitals Oncology Chain Business Plan, June 2026.)

Phase 1 · FY27–FY29
1 → 4 units
40 → 160 beds

Flagship upgrade in Hyderabad + first metro cluster (Series A ≈ ₹150 Cr).

Phase 2 · FY30–FY33
4 → 12 units
160 → 480 beds

Fill the 8-km metro grid, cell-by-cell, plus a second & third LINAC centre.

Phase 3 · FY34–FY36
12 → 18 units
480 → 720 beds

Complete the metro network; replicate in adjacent Tier-1 and Tier-2 cities.

Disclaimer: Projections are illustrative and subject to material change. This is not an offer of securities or investment advice.

Tier-2 & Tier-3 access strategy

Where the radiotherapy deficit is most acute, we go first.

India needs more than a thousand radiotherapy facilities; only a few hundred exist, and most are clustered in metros. Our spoke-first replication plan brings daycare chemotherapy, diagnostics and tele-radiology to district capitals — feeding a hub-LINAC when complex radiation is required.

Anjaniputra Hospitals exterior
Tier-1 Hub
Comprehensive Cancer Centre + multi-speciality

LINAC, MRI, 128-CT, NGS lab, modular OT, 60-bed inpatient

Tier-2 Cluster
40-bed oncology unit + radiation feasibility

Daycare chemo, CT-sim, mammography, AERB-sited LINAC where viable

Tier-3 Spoke
Near-home cancer day-care & follow-up

Modular OT, CT, ultrasound, infusion bays, telemedicine link to hub

Find a doctor

Search by specialisation, city, experience or practice status.

26 doctors match your filters
Dr. Venkateswara Rao Tangella

Dr. Venkateswara Rao Tangella

Cardiology

MBBS, MD, DNB, PGDHSC

Hyderabad24 yrsPractising
in
Dr. Vinodh Kumar

Dr. Vinodh Kumar

Critical Care

MBBS, MD, DM, FCCM

Hyderabad18 yrsPractising
in
Dr. Rajkumar Jaipal

Dr. Rajkumar Jaipal

Surgery

MBBS, M.S. (Gen. Surgery)

Ajmer28 yrsVisiting
in
Dr. Khaleda Adib Binte Abdullah

Dr. Khaleda Adib Binte Abdullah

Regenerative Medicine

MBBS, D.Sc, PhD

Lugano22 yrsVisiting
in
Dr. Pavan

Dr. Pavan

Neurology

MBBS, Neurology

Hyderabad9 yrsPractising
in
Dr. Ravi Khant

Dr. Ravi Khant

Critical Care

MBBS, Fellow Critical Care

Hyderabad12 yrsPractising
in
Dr. Anupama Raghavan

Dr. Anupama Raghavan

Diagnostics

MBBS (Yangzhou University)

Bengaluru7 yrsPractising
in
Dr. Bharath Prathipati

Dr. Bharath Prathipati

Public Health

MBBS, MS Global Health (Canada)

Toronto11 yrsVisiting
in
Dr. Mani Shankar

Dr. Mani Shankar

Critical Care

MBBS, FCCM, DM Diabetology

Hyderabad15 yrsPractising
in
Dr. Srija Madella

Dr. Srija Madella

Pulmonology

MBBS, MD Pulmonology Resident

Hyderabad5 yrsPractising
in
Dr. K Sailaja

Dr. K Sailaja

Pulmonology

MBBS, MD (Pulmonology)

Hyderabad16 yrsPractising
in
Dr. D. Ram Mohan Roy

Dr. D. Ram Mohan Roy

Endocrinology

MBBS, DTCD, MD Internal Medicine

Hyderabad20 yrsPractising
in
Dr. Shivaranjani Chinta

Dr. Shivaranjani Chinta

Administration

MBA (Healthcare Management)

Hyderabad10 yrsPractising
in
Dr. Srikanth Kongara

Dr. Srikanth Kongara

Endocrinology

MBBS, MD (AIIMS), DM (SGPGI)

Hyderabad17 yrsPractising
in
Dr. Neeraja Kunireddy

Dr. Neeraja Kunireddy

Pathology

MBBS, MD

Hyderabad13 yrsPractising
in
Dr. Ravi Kumar

Dr. Ravi Kumar

Critical Care

MBBS, Doctor of Medicine

Hyderabad14 yrsPractising
in
Dr. Sourabh

Dr. Sourabh

Administration

MBBS

Hyderabad8 yrsPractising
in
Dr. M. Raghunath Babu

Dr. M. Raghunath Babu

Endocrinology

MBBS, MD Diabetology

Hyderabad19 yrsPractising
in
Dr. Moksha Rayalu

Dr. Moksha Rayalu

Research

PhD in Biostatistics

Visakhapatnam12 yrsVisiting
in
Dr. Taslimarif Saiyed

Dr. Taslimarif Saiyed

Research

PhD (Max-Planck), Wharton

Bengaluru21 yrsVisiting
in
Dr. Venkateshwara Rao Tangella

Dr. Venkateshwara Rao Tangella

Cardiology

MBBS, MD, PGDHSC, DNB

Hyderabad23 yrsPractising
in
Dr. Raghunath Babu

Dr. Raghunath Babu

Endocrinology

MBBS, PG Diabetology (NIMS)

Hyderabad18 yrsPractising
in
Dr. J. AL. Ranganath

Dr. J. AL. Ranganath

Nephrology

MBBS, MD, DM (Nephrology)

Chennai25 yrsPractising
in
Dr. Gnapika Chowdary

Dr. Gnapika Chowdary

Paediatrics

MBBS, MD (Intl. Higher School)

Hyderabad6 yrsPractising
in
Dr. Arun Kumar Kedia

Dr. Arun Kumar Kedia

Pulmonology

MBBS, MD Pulmonology

Kolkata22 yrsVisiting
in
Dr. Rahul Agarwal

Dr. Rahul Agarwal

Vascular Surgery

MBBS, DNB (Gen. Surg.), DrNB (Vasc.)

Delhi16 yrsVisiting
in
Our clinicians

Physicians who lead their fields.

Hover or touch the strip to pause. Our consultant panel spans oncology, cardiology, nephrology, pulmonology, surgery, endocrinology, critical care and biomedical research.

Dr. Venkateswara Rao Tangella

Dr. Venkateswara Rao Tangella

Interventional Cardiology · Medical Director

MBBS, MD, DNB, PGDHSC

LinkedIn profile →
Dr. Venkateswara Rao Tangella

Dr. Venkateswara Rao Tangella

Interventional Cardiology · Medical Director

MBBS, MD, DNB, PGDHSC

LinkedIn profile →
Our network

One brand, three continents — same standard of care.

The Hyderabad flagship anchors the chain. Partner clinics in Switzerland and Canada extend our reach to bio-regenerative medicine in Europe and diaspora second-opinion care in North America.

Anjaniputra Hospitals Hyderabad flagship building exterior at golden hour
Anjaniputra · Asia
Asia

Hyderabad

Flagship · India

Comprehensive oncology hub with closed ICU, LINAC suite and the 8-km metro grid headquarters.

Anjaniputra Hospitals Hyderabad reception lobby with brand signage
Anjaniputra Hospitals Hyderabad oncology day-care floor
Anjaniputra Hospitals Lugano partner clinic exterior overlooking Lake Lugano
Anjaniputra · Europe
Europe

Lugano

Partner Clinic · Switzerland

Bio-regenerative medicine partner for autologous cell, peptide and exosome protocols, integrated with oncology care in India.

Anjaniputra Hospitals Lugano regenerative medicine consultation suite
Anjaniputra Hospitals Lugano peptide and cell-therapy preparation laboratory
Anjaniputra Hospitals Toronto partner centre glass tower at dusk
Anjaniputra · North America
North America

Toronto

Partner Centre · Canada

Diaspora-facing partner centre for second opinions, public-health programmes and integrative survivorship care.

Anjaniputra Hospitals Toronto reception with double-height lobby
Anjaniputra Hospitals Toronto integrative wellness lounge

Architectural and interior visuals shown here are representative renders of the Anjaniputra Hospitals brand experience across centres; partner-clinic affiliations are subject to local regulatory frameworks.

Doctors · Partner with us

Bring your practice to a chain built around the patient — and the clinician.

We invite consultants, surgeons and oncologists to partner with Anjaniputra Hospitals across our metro grid and Tier-2/Tier-3 spokes. Equity, revenue-share, fellowship and visiting-faculty pathways are all available.

  • Equity participation in the unit you lead
  • Transparent revenue-share, no kickbacks
  • Shared tumour-board, NGS lab, central EMR
  • Marketing, billing & RCM handled centrally
  • Fellowship & teaching pathways
  • International protocol-development committees
Partner with Anjaniputra

We respond within two business days. All enquiries are confidential.

Why choose Anjaniputra

Six benchmarks where Anjaniputra is built differently from comparable top hospital networks.

Each card names the benchmark, our measured commitment, the industry-typical pattern at peer multi-speciality networks, and the patient-side outcome. Every metric links to the public source we benchmarked against — so the comparison can be checked, not just trusted.

Physician-led governance

Benchmark: Who decides the treatment plan

Head-to-head

Anjaniputra

Clinician-owned chain with a single chain-wide tumour board reviewing every Stage III/IV case within 7 days.

Comparable top hospitals

Corporate-owned networks where multidisciplinary boards meet hospital-by-hospital, often fortnightly.

One unified plan across centres — patients are not re-staged or re-billed when they move units.

SourcesApollo MDT charter ↗Manipal tumour board ↗

Near-home access geometry

Benchmark: Distance from patient's home to advanced care

Head-to-head

Anjaniputra

Tier-2/3 spoke hubs (Warangal, Karimnagar, Khammam) feeding the Hyderabad flagship — chemo & dialysis within 90 minutes of home.

Comparable top hospitals

Advanced oncology and transplant concentrated in 8–10 Tier-1 metros; many patients travel 300+ km per cycle.

Lower travel burden, higher chemotherapy adherence, fewer treatment interruptions.

SourcesNCDIR India cancer atlas ↗Lancet Oncology access gap (India) ↗

Diagnostic turnaround time

Benchmark: Hours from sample/scan to actionable report

Head-to-head

Anjaniputra

Imaging ≤ 4 h · Histopathology ≤ 48 h · Tumour-board decision ≤ 7 days, monitored chain-wide.

Comparable top hospitals

Industry-typical biopsy turnaround in Indian tertiary centres is 5–10 working days; MDT cadence 2–3 weeks.

Treatment starts 1–2 weeks sooner — and in oncology, time-to-treatment is an outcome driver.

SourcesCAP histopathology TAT guideline ↗JCO time-to-treatment study ↗

Pricing transparency

Benchmark: What the patient knows before admission

Head-to-head

Anjaniputra

Published package rates for 120+ procedures; written pre-authorised estimates with a ±10% variance commitment.

Comparable top hospitals

Estimate-on-admission is the norm; revised bills at discharge are common patient complaints.

Families plan finances with confidence — no bill-shock, no last-mile borrowing.

SourcesAyushman Bharat package rates ↗NPPA hospital charges advisory ↗

Data protection & portability

Benchmark: Patient control over the medical record

Head-to-head

Anjaniputra

HIPAA-grade access controls, audit trail per record view, one-click patient export via ABHA.

Comparable top hospitals

Hospital-owned EMRs; record requests typically take 3–7 working days and are paper-based.

Your record travels with you — second opinions, insurance and overseas care are friction-free.

SourcesABDM / ABHA framework ↗HHS HIPAA Security Rule ↗

Ethics & disclosure

Benchmark: What the hospital publishes about itself

Head-to-head

Anjaniputra

Public ethics charter, conflict-of-interest register for consultants, and a patient-doctor privilege policy aligned to MCI Regulation 7.14.

Comparable top hospitals

Internal codes of conduct are common; public ethics charters and COI registers are rare.

Patient-doctor privilege is treated as a legal duty, not a marketing line.

SourcesNMC Code of Ethics (Reg. 7.14) ↗WMA Declaration of Geneva ↗

Comparison FAQ

How to read the benchmark cards, what the data covers, and where to check it.

They measure structural and operational dimensions that directly shape patient experience — access geometry, treatment turnaround time, infection control, cost transparency, precision technology, and ethics governance — not subjective brand preference.

Glossary — how to read benchmark terms

Plain-language definitions of the terms we use across the comparison cards and FAQ.

Outcomes
Measurable clinical results after treatment — survival, complication and readmission rates. Read alongside case-mix: hospitals treating sicker patients may report different numbers than those treating routine cases.
Wait times / Turnaround time
How long from request to result or treatment — appointment, imaging report, biopsy, surgery. Shorter is usually better, but only when paired with diagnostic accuracy and follow-through.
Accreditation
Independent verification of safety and quality standards (e.g. NABH in India, JCI internationally). It certifies the operating system of a hospital, not the outcome of any individual case.
Access geometry
How physically reachable care is for a defined population — distance, drive time and unit density. A dense 8-km grid reduces delay-to-treatment for time-sensitive conditions.
Cost transparency
Whether package and itemised prices are published before admission. Transparent pricing lets patients compare and consent meaningfully; it does not by itself imply the lowest price.
Ethics governance
Documented rules on conflicts of interest, second opinions, advertising and patient–doctor privilege. Stronger governance protects clinical decisions from commercial pressure.

"Comparable top hospitals" describes the industry-typical operating model observed across leading multi-speciality networks in India, summarised from the publicly available sources linked on each card (accessed June 2026). Anjaniputra figures are the chain's own published service-level commitments. Indicative — not a critique of any named institution, and not a substitute for individual clinical advice. Trademarks belong to their respective owners.

Benchmarking

How we compare with India's leading hospital networks.

A transparent, structural comparison against the best comparable multi-speciality networks. We benchmark on access geometry and operating model — not on naming or out-performing any individual institution.

DimensionAnjaniputraApolloManipal
Average distance to chemotherapy≤ 8 km (near-home grid)Hub-led, city-wideHub-led, city-wide
FormatUniform 40-bed cellsLarge multi-specialty hubsLarge multi-specialty hubs
Oncology depthSingle-specialty platformMulti-specialtyMulti-specialty
Tier-2 & Tier-3 accessPlanned spokes from year 4SelectiveSelective
Doctor-partnership modelEquity & revenue-share invitedSalaried + consultingSalaried + consulting

Disclaimer: Comparative data drawn exclusively from publicly available sources — peer-hospital websites, published service-level statements, annual reports and reputable industry publications — as of June 2026. Indicative, not exhaustive, and not intended to disparage any institution. Trademarks belong to their respective owners.

International standards · JCI-aligned

The protocols our patients deserve — written down, audited, and shared.

Anjaniputra Hospitals operates to JCI-aligned protocols — the same patient-safety, infection-control and clinical-governance standards used by leading hospitals in Singapore, Bangkok and the United States. We publish what we measure.

  • 01

    International Patient Safety Goals (IPSG-aligned) — patient identification, effective communication, high-alert medication safety, surgical-site verification, infection control, fall-risk reduction.

  • 02

    Daily multidisciplinary tumour board for every confirmed malignancy.

  • 03

    Closed-loop medication ordering with double-check on cytotoxic agents.

  • 04

    AERB-compliant radiation safety, dosimetry audits and weekly QA on LINAC.

  • 05

    Hand-hygiene compliance monitoring with monthly reporting.

  • 06

    Sepsis bundles, VAP bundles, CLABSI surveillance with public-facing dashboards.

  • 07

    Informed-consent pathway in the patient's preferred language.

  • 08

    Mortality, morbidity and near-miss review at unit and chain level.

  • 09

    Continuous staff credentialing & re-credentialing aligned to international norms.

Patient–Doctor privilege

What you tell us, stays with us.

The conversation between a patient and a clinician is one of the most protected exchanges in medicine. We take that responsibility seriously — beyond what the law requires.

  • 1Every consultation room is sound-isolated; conversations cannot be overheard at reception or in adjoining rooms.
  • 2Clinical notes are visible only to the treating consultant, the care manager you nominate, and the regulators who legally require access.
  • 3Family members are briefed only with your written or recorded verbal consent — even in critical care.
  • 4We will never disclose your diagnosis to an employer, insurer or third party without your explicit, granular consent.
  • 5Genomic and HIV/AIDS-related records are stored on a segregated, access-controlled tier with dual-authorisation for retrieval.
  • 6Second opinions you seek elsewhere are not shared with our own consultants unless you choose to share them.
  • 7If our system is ever compromised, you will hear it from us first — within 72 hours, in plain language, with a remediation plan.
Framed portrait of Hippocrates of Kos reading the original Oath, hung in a hospital corridor
The Hippocratic Oath

"First, do no harm."

The Oath of Hippocrates — taken by physicians for more than two millennia — is displayed in the corridor outside every consultation block at Anjaniputra Hospitals. It is a daily reminder of the contract our clinicians hold with the people who walk through our doors.

"I will use those dietary regimens which will benefit my patients according to my greatest ability and judgement, and I will do no harm or injustice to them … Whatever I see or hear in the lives of my patients, whether in connection with my professional practice or not, which ought not to be spoken of outside, I will keep secret, as considering all such things to be private."

— Modern English rendering of the Oath of Hippocrates (c. 5th century BCE), adapted from the W.H.S. Jones translation.

Our promise

An ethics charter, in plain language.

Healthcare loses its meaning the moment money decides the medicine. Our charter is short, public, and binding on every clinician and administrator who wears our coat.

  • 1

    We will never recommend a treatment we would not offer our own family.

  • 2

    Second opinions are encouraged and never penalised.

  • 3

    Transparent pricing — every estimate shared in writing before admission.

  • 4

    No commissions, kick-backs or referral incentives, ever.

  • 5

    Patient data is held in strict confidence, beyond the legal minimum.

A sensible approach to advertising

We market with restraint. We invest in trust.

We do not buy "miracle-cure" testimonials. We do not pay for influencers to describe medical procedures. We do not run scarcity-driven campaigns ("only 3 slots left this week") for life-altering decisions.

What we do invest in: free public-health webinars, patient-education content reviewed by our consultants, community early-detection camps in Tier-2 cities, and clear written estimates before any treatment is initiated.

Every claim on this website is reviewed by our medical advisory board. If you spot a claim you'd like sourced, write to care@anjaniputra.com and we will share the reference.

With gratitude

Credits to the founders of modern medication & cellular medicine.

Our clinical programmes stand on the shoulders of the pioneers who shaped modern oncology, cell therapy and regenerative medicine. We acknowledge them gratefully — without them, none of what we do would be possible.

Dr. Sidney Farber
Father of modern chemotherapy
Dr. Paul Niehans
Pioneer of cellular therapy (Switzerland)
Prof. Mikhail Voronoff
Early regenerative medicine
Dr. Emil Frei & Dr. Emil Freireich
Combination chemotherapy (leukaemia)
Dr. Bernard Fisher
Breast-cancer trial methodology
Prof. Mikhail Lukashev & European Wellness lineage
Modern peptide & organ-specific therapy
Dr. Mike Chan & Dato' Sri Prof. Mike K. S. Chan
Contemporary biological-medicine science
Dr. James Allison & Dr. Tasuku Honjo
Cancer immunotherapy (Nobel 2018)
Dr. Brian Druker
Targeted therapy (imatinib)

This is a non-exhaustive list maintained in good faith. Suggestions for additions are welcome at care@anjaniputra.com.

Begin your care journey

Speak with our care concierge.

Same-day appointments. Second opinions reviewed by senior consultants. Cashless across leading insurers.